US Stock MarketDetailed Quotes
ABVC ABVC BioPharma
- 0.5499
- -0.0175-3.08%
Close Nov 21 16:00 ET
- 0.5500
- +0.0001+0.02%
Post 16:55 ET
7.14MMarket Cap-678P/E (TTM)
0.5900High0.5300Low88.94KVolume0.5850Open0.5674Pre Close49.50KTurnover0.88%Turnover RatioLossP/E (Static)12.98MShares2.450052wk High0.85P/B5.57MFloat Cap0.405352wk Low--Dividend TTM10.13MShs Float116.9000Historical High--Div YieldTTM10.58%Amplitude0.4053Historical Low0.5560Avg Price1Lot Size
ABVC BioPharma Stock Forum
Sign in to post a comment
$ABVC BioPharma (ABVC.US)$
ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners
ABVC BioPharma has received an additional $50,000 in licensing fees from AiBtl BioPharma Inc., bringing the total payments from strategic partners to $346,000. This payment is part of a broader agreement related to ABVC's psychiatric disorder pipeline, which includes treatments for Major Depressive Disorder (MDD) and Attention Deficit ...
ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners
ABVC BioPharma has received an additional $50,000 in licensing fees from AiBtl BioPharma Inc., bringing the total payments from strategic partners to $346,000. This payment is part of a broader agreement related to ABVC's psychiatric disorder pipeline, which includes treatments for Major Depressive Disorder (MDD) and Attention Deficit ...
$ABVC BioPharma (ABVC.US)$ Reuters· just
ABVC Biopharma- Got Written Notification From Nasdaq, Indicating Co Regained Compliance With Listing Rules 5635(a)(1) and 5635(a)(2)
ABVC Biopharma- Got Written Notification From Nasdaq, Indicating Co Regained Compliance With Listing Rules 5635(a)(1) and 5635(a)(2)
2
$ABVC BioPharma (ABVC.US)$ Financial Performance:
- Earnings Per Share (EPS): Demonstrated a remarkable year-over-year improvement of approximately 86.8%, with EPS improving to -$0.09 in Q2 2024 from -$0.68 in the same period last year. This significant progress reflects our successful efforts in managing operational expenses and capitalizing on milestone payment revenue from licensing agreements.
- Revenue Growth: Revenue increased to $117,142 in Q2 2024, a substantial rise from $6,109...
- Earnings Per Share (EPS): Demonstrated a remarkable year-over-year improvement of approximately 86.8%, with EPS improving to -$0.09 in Q2 2024 from -$0.68 in the same period last year. This significant progress reflects our successful efforts in managing operational expenses and capitalizing on milestone payment revenue from licensing agreements.
- Revenue Growth: Revenue increased to $117,142 in Q2 2024, a substantial rise from $6,109...
1
Some Top Moo_vers in AH’s trading.
$Bright Minds Biosciences (DRUG.US)$ $ABVC BioPharma (ABVC.US)$ $SAI TECH Global (SAI.US)$ $Addentax (ATXG.US)$ $Chuy's Holdings (CHUY.US)$
$Bright Minds Biosciences (DRUG.US)$ $ABVC BioPharma (ABVC.US)$ $SAI TECH Global (SAI.US)$ $Addentax (ATXG.US)$ $Chuy's Holdings (CHUY.US)$
3
$ABVC BioPharma (ABVC.US)$ about time. 🏃♂️
1
1
$ABVC BioPharma (ABVC.US)$ Reuters· just
ABVC Biopharma Inc - Collaboration Between ABVC and Oncox Biopharma, ABVC Expecting Aggregate Income of $13.75 Mln and Royalties of up to $12.50 Mln
ABVC Biopharma Inc - Collaboration Between ABVC and Oncox Biopharma, ABVC Expecting Aggregate Income of $13.75 Mln and Royalties of up to $12.50 Mln
3
2
Closed at the 1.53 support level. Will be watching tomorrow for a push into the POC starting at 1.71. 1.38 is critical to hold.
Larger Image: tradingview.com...
$ABVC BioPharma (ABVC.US)$
Larger Image: tradingview.com...
$ABVC BioPharma (ABVC.US)$
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
周淮安 : What do you think will happen here?
Jaguar8 OP 周淮安 : No volume as of this time